Home » Stocks » GLMD

Galmed Pharmaceuticals Ltd. (GLMD)

Stock Price: $3.81 USD -0.01 (-0.26%)
Updated Jan 26, 2021 10:02 AM EST - Market open
Market Cap 81.41M
Revenue (ttm) n/a
Net Income (ttm) -20.46M
Shares Out 21.11M
EPS (ttm) -1.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 26
Last Price $3.81
Previous Close $3.82
Change ($) -0.01
Change (%) -0.26%
Day's Open 4.00
Day's Range 3.75 - 4.03
Day's Volume 102,916
52-Week Range 3.06 - 6.35

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 1 month ago

TEL AVIV, Israel, Dec. 17, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and infl...

Seeking Alpha - 2 months ago

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q3 2020 Results - Earnings Call Transcript

PRNewsWire - 4 months ago

TEL-AVIV, Israel and SHANGHAI, Sept. 10, 2020 /PRNewswire/ -- Gannex Pharma Co.

PRNewsWire - 4 months ago

SHANGHAI and TEL-AVIV, Israel, Sept. 9, 2020 /PRNewswire/ -- Gannex Pharma Co.

Seeking Alpha - 5 months ago

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q2 2020 Results - Earnings Call Transcript

PRNewsWire - 5 months ago

TEL AVIV, Israel, Aug. 6, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd.

PRNewsWire - 5 months ago

TEL AVIV, Israel, Aug. 6, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd.

Zacks Investment Research - 7 months ago

Galmed (GLMD) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Seeking Alpha - 8 months ago

Galmed Pharmaceuticals Ltd (GLMD) CEO Allen Baharaff on Q1 2020 Results - Earnings Call Transcript

PRNewsWire - 8 months ago

TEL AVIV, Israel, May 14, 2020 /PRNewswire/ --Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of t...

Seeking Alpha - 10 months ago

Galmed Pharmaceuticals Ltd (GLMD) CEO Allen Baharaff on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Top Ranked Momentum Stocks to Buy for December 4th

Other stocks mentioned: CAAS, GSAT, SAVA
Zacks Investment Research - 1 year ago

NASH sees a highly rewarding market with candidates of blockbuster potential. Let us take a look at the hits and misses in this space so far this year.

Other stocks mentioned: AGN, CBAY, CNAT, ICPT, MDGL
Seeking Alpha - 1 year ago

Galmed Pharmaceuticals Ltd (GLMD) CEO Allen Baharaff on Q3 2019 Results - Earnings Call Transcript

24/7 Wall Street - 1 year ago

While most of Wall Street focuses on large and mega cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: CPE, SIEN, TELL, VKTX
Seeking Alpha - 1 year ago

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q2 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q1 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Galmed Pharmaceuticals (GLMD) delivered earnings and revenue surprises of 10.53% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for ...

24/7 Wall Street - 1 year ago

This off-the radar pick could be poised to be a huge winner. Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) is a clinical-stage biopharmaceutical company.

Other stocks mentioned: INO, LJPC, MNKD, VKTX
Zacks Investment Research - 1 year ago

Galmed Pharmaceuticals delivered earnings and revenue surprises of -58.33% and -100.00%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the...

About GLMD

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in ARREST Phase III pivotal study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity, and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and ... [Read more...]

Industry
Biotechnology
IPO Date
Mar 13, 2014
CEO
Allen Baharaff
Employees
17
Stock Exchange
NASDAQ
Ticker Symbol
GLMD
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for GLMD stock is "Buy." The 12-month stock price forecast is 17.80, which is an increase of 367.19% from the latest price.

Price Target
$17.80
(367.19% upside)
Analyst Consensus: Buy